Twist Bioscience Corporation
A maker of synthetic DNA, Twist Bioscience writes custom genes and gene fragments on tiny silicon chips, shrinking the synthesis process dramatically. Its tools help researchers and drug developers discover and optimize antibodies, while its NGS products—target enrichment probes, library prep kits, and synthetic controls—are used in diagnostic tests for cancer, rare disease, and infectious disease. The company serves over 3,800 customers worldwide.
Granted 1.16M · Sold 520.9K
Granted 140.1K · Sold 95.3K
Granted 557.3K · Sold 349.4K
Granted 247.1K · Sold 140.3K
Granted 179.4K · Sold 70.3K
Granted 27.1K
Granted 114.0K · Sold 51.0K
Granted 172.8K · Bought 10.0K · Sold 91.6K
Granted 44.2K · Sold 43.6K
Granted 21.5K · Sold 19.3K
Granted 83.0K · Sold 35.5K
Granted 5.1K
Granted 31.1K
Granted 49.1K · Sold 33.2K
Granted 27.1K
Granted 22.0K
Granted 12.6K · Bought 8.6K
Granted 27.1K · Sold 6.2K
Granted 19.4K
Granted 9.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leproust Emily M.Chief Executive Officer, Director · 192 transactions | +208.8% | 770.7K | 1.16M | — | 520.9K |
| Banyai WilliamSee Remark · 88 transactions | +2.4% | 345.2Kas of May 2024 | 140.1K | — | 95.3K |
| Finn Patrick JohnPresident and COO · 132 transactions | +429.3% | 210.8K | 557.3K | — | 349.4K |
| Green PaulaSVP of Human Resources · 103 transactions | +505.8% | 117.9K | 247.1K | — | 140.3K |
| Laponis AdamChief Financial Officer · 31 transactions | — | 108.6K | 179.4K | — | 70.3K |
| Crandell KeithDirector · 5 transactions | +28.7% | 103.6K | 27.1K | — | — |
| Thorburn James MChief Financial Officer · 81 transactions | +90.8% | 86.3Kas of Jan 2024 | 114.0K | — | 51.0K |
| Cho DennisSee Remarks · 94 transactions | — | 74.1K | 172.8K | 10.0K | 91.6K |
| Chess RobertDirector · 22 transactions | — | 63.6K | 44.2K | — | 43.6K |
| Weiss PatrickChief Operating Officer · 24 transactions | -3.7% | 47.4Kas of Apr 2022 | 21.5K | — | 19.3K |
| Werner Robert F.Chief Accounting Officer · 52 transactions | — | 44.6K | 83.0K | — | 35.5K |
| Chan NelsonDirector · 1 transaction | — | 33.3K | 5.1K | — | — |
| Mai XiaoyingDirector · 4 transactions | — | 31.1Kas of Feb 2024 | 31.1K | — | — |
| Johannessen JanDirector · 15 transactions | +1467.7% | 29.8K | 49.1K | — | 33.2K |
| Ragusa Robert PDirector · 5 transactions | +132.1% | 29.0K | 27.1K | — | — |
| Chan Nelson CDirector · 4 transactions | +356.6% | 28.2Kas of Feb 2025 | 22.0K | — | — |
| Barthelemy NicolasDirector · 3 transactions | +1112.9% | 23.0Kas of Nov 2022 | 12.6K | 8.6K | — |
| Starovasnik Melissa A.Director · 10 transactions | — | 22.2K | 27.1K | — | 6.2K |
| Blake KatrynDirector · 2 transactions | — | 19.4K | 19.4K | — | — |
| Yankton Kevin BruceChief Accounting Officer · 18 transactions | +469.3% | 9.1Kas of May 2023 | 9.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.44M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.